Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RICH-VICKS IS THE ONLY BREEZE ON A SULTRY AUGUST INDEX; COMPOSITE DIPS BELOW 600

Executive Summary

Rich-Vicks (up 2-5/8 to 38-1/2) was the single bright spot on the "F-D-C" Weekly Index for the week ended Aug. 9. The company's 7.3% rise, fueled in part by continued rumors that the firm is for sale, defied the overall trend on Wall Street. McKesson (up 1/8 to 41-7/8) and American Home (up 1/4 to 60-1/4) were the only other of the 24 Diversifieds which showed any increase. Carter-Wallace (down 4 to 34) was the big loser after the company announced early last week that it had stopped clinical trials for its heart drug, bepridil. The Composite dipped below the 600 level for the first time since June 24. Its 1.7% decrease from the previous week kept it slightly ahead of the Dow Jones average, which dropped 2.4%, finishing the week at 1320.79. Erbamont (up 3/8 to 12) and Searle (up 3/8 to 64-7/8) were the only Pharmaceuticals posting gains, while among the Chains, Genovese (up 1/4 to 12-1/4) and Perry (up 1-3/4 to 22-3/4 were the sole winners. Chart omitted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel